The AP5S1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of the A-549 human lung adenocarcinoma epithelial cell line, featuring targeted disruption of the AP5S1 gene. This heterogeneous pool provides a loss-of-function model for studying the AP-5 adaptor complex in endosomal trafficking and autophagy, without clonal selection.
The A-549 cell line originates from human lung adenocarcinoma and displays type II alveolar epithelial characteristics, serving as a standard model for lung cancer research. Its well-characterized biology and responsiveness to therapeutics make it a rational host for examining genetic perturbations relevant to lung adenocarcinoma pathophysiology.
AP5S1 encodes the sigma1 subunit of the AP-5 complex, which mediates retrograde transport from late endosomes to the trans-Golgi network. The complex, also containing AP5Z1, AP5M1, and AP5B1, acts downstream of mTORC1 and is transcriptionally upregulated by TFEB. AP5S1 interacts with SPG11 and SPG15 to coordinate lysosomal enzyme trafficking; its loss disrupts autophagic clearance, causing accumulation of LC3 and p62. Thus, knockout of AP5S1 impairs lysosomal homeostasis and autophagic flux, providing a tool to investigate mTORC1/TFEB-regulated degradation pathways.
In A-549 cells, AP5S1 deficiency may alter cancer cell properties including proliferation, migration, and drug sensitivity, as autophagy and lysosomal function are key determinants of tumor cell survival. This polyclonal model enables researchers to explore how defective endosomal-lysosomal trafficking modulates lung adenocarcinoma pathogenesis, potentially uncovering targetable vulnerabilities.
Applications include Western blotting for LC3 and p62, immunofluorescence of LAMP1/2, RT-qPCR of autophagy genes, MTT proliferation assays, drug sensitivity screens, transwell migration assays, and co-immunoprecipitation of AP-5 components. This model supports investigations into AP-5 biology in cancer, autophagy dysfunction, and drug response. For inquiries, contact Ascent Research.
